Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Key Highlights
- ➤Pevifoscorvir sodium Phase 2 enrollment completed with 245 participants across two cohorts
- ➤Topline B-SUPREME data expected in late Q3 2027
- ➤Cash, equivalents and investments fell to $31.1 million from $77.8 million
- ➤Cash expected to fund planned operations into the first quarter of 2027
- ➤Third-quarter net loss narrowed to $21.9 million from $31.5 million
Expert Statements
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027.”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout.”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop.”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.
“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”
Get started
Create a free account to read the full story.